PDF(Pubmed)
Abstract：
OBJECTIVE: The objective of this study is to systemically review the literature on Anterior Saphenous Vein (ASV) reflux treatment and insurance impediments to treatment coverage.
METHODS: A literature search was performed using a PRISMA framework. In addition, a cross-sectional analysis of insurance policies for ASV treatment was evaluated.
RESULTS: Published evidence and treatment considerations in the literature for ASV treatment are discussed. In 155 of 226 (68.6%) insurance policies reviewed coverage of ASV ablation was allowed while 62/226 (27.4%) did not specify coverage and 9/226 (4.0%) specified ASV treatment was not covered. Of the 155 that provide ASV coverage, 98 (62.2%) provide coverage with criteria such as requiring prior treatment of the great saphenous vein.
CONCLUSIONS: Vein treatment experts should continue to advocate to insurance carriers to update their varicose vein treatment policies to reflect the substantial clinical evidence so that patients with ASV reflux can be appropriately treated.
METHODS: A literature search was performed using a PRISMA framework. In addition, a cross-sectional analysis of insurance policies for ASV treatment was evaluated.
RESULTS: Published evidence and treatment considerations in the literature for ASV treatment are discussed. In 155 of 226 (68.6%) insurance policies reviewed coverage of ASV ablation was allowed while 62/226 (27.4%) did not specify coverage and 9/226 (4.0%) specified ASV treatment was not covered. Of the 155 that provide ASV coverage, 98 (62.2%) provide coverage with criteria such as requiring prior treatment of the great saphenous vein.
CONCLUSIONS: Vein treatment experts should continue to advocate to insurance carriers to update their varicose vein treatment policies to reflect the substantial clinical evidence so that patients with ASV reflux can be appropriately treated.
摘要：
目的：本研究的目的是系统回顾有关前隐静脉（ASV）反流治疗和治疗范围的保险障碍的文献。
方法：使用PRISMA框架进行文献检索。此外,对ASV治疗保险单的横断面分析进行了评估.
结果：讨论了文献中关于ASV治疗的公开证据和治疗考虑。在226份（68.6%）的保险中，有155份保险允许ASV消融的承保范围，而62/226份（27.4%）未指定承保范围，9/226份（4.0%）指定的ASV治疗未承保。在提供ASV覆盖的155个中，98（62.2％）提供了覆盖标准，例如需要对大隐静脉进行事先治疗。
结论：静脉治疗专家应继续倡导保险公司更新其静脉曲张治疗政策，以反映大量临床证据，以便ASV反流患者可以得到适当治疗。
方法：使用PRISMA框架进行文献检索。此外,对ASV治疗保险单的横断面分析进行了评估.
结果：讨论了文献中关于ASV治疗的公开证据和治疗考虑。在226份（68.6%）的保险中，有155份保险允许ASV消融的承保范围，而62/226份（27.4%）未指定承保范围，9/226份（4.0%）指定的ASV治疗未承保。在提供ASV覆盖的155个中，98（62.2％）提供了覆盖标准，例如需要对大隐静脉进行事先治疗。
结论：静脉治疗专家应继续倡导保险公司更新其静脉曲张治疗政策，以反映大量临床证据，以便ASV反流患者可以得到适当治疗。
